Barusiban
Also known as: Barusiban, FE 200440, FE200440, SRI-37618
Source Barusiban at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Barusiban is a synthetic cyclic peptide designed to selectively block the oxytocin receptor. It has been investigated in clinical trials for the inhibition of preterm labor but has not received regulatory approval.
Mechanism of Action
Competitive antagonist at the oxytocin receptor, preventing oxytocin‑mediated uterine smooth‑muscle contraction
Routes of Administration
Goals & Uses
- Inhibition of preterm laborObstetric / TocolysisModerate
- Improved tocolytic tolerability vs atosibanSafety / PharmacologyLow
- Preterm labor suppressionObstetricsModerate
- Reduction of uterine contractionsObstetricsModerate
Contraindications
- Hypersensitivity to barusiban or related peptidesAllergyHigh
- Severe fetal distressObstetricHigh
- Intrauterine infection / chorioamnionitisObstetricHigh
- Severe maternal hypertensionCardiovascularModerate
- Placenta previa with active bleedingObstetricHigh
Adverse Effects
- Cardiovascular effects (tachycardia, hypotension)CardiovascularRare
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- OxytocinModerate
- Ergot alkaloids (e.g., ergometrine)Moderate
Population Constraints
- Multiple gestationObstetricRelative
- Pregnant women beyond 34 weeks gestationObstetric TimingRelative
- Gestational age < 24 weeks or > 34 weeksObstetricRelative
- Hepatic or renal impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionInvestigationalNot authorized for marketing in the European Union
- United StatesInvestigationalNo FDA approval; studied in Phase II trials for preterm labor
- United KingdomInvestigationalNot MHRA-approved; research use only.
Development discontinued after phase II trials; not approved in any jurisdiction.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Barusiban?
Barusiban is a synthetic cyclic peptide designed to selectively block the oxytocin receptor. It has been investigated in clinical trials for the inhibition of preterm labor but has not received regulatory approval.
What is Barusiban used for?
Barusiban is educationally associated with: Inhibition of preterm labor, Improved tocolytic tolerability vs atosiban, Preterm labor suppression, Reduction of uterine contractions. Educational only — not medical advice.
How is Barusiban administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Barusiban?
Reported adverse effects include: Cardiovascular effects (tachycardia, hypotension), Injection site reactions, Headache, Nausea, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Barusiban?
Recorded contraindications: Hypersensitivity to barusiban or related peptides, Severe fetal distress, Intrauterine infection / chorioamnionitis, Severe maternal hypertension, Placenta previa with active bleeding. Consult a qualified clinician before use.